Molecular Targets in the Treatment of Non—Small-Cell Lung Cancer: Is There Hope on the Horizon?

References

• . Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29
   PubMed Web of Science ®Google Scholar
• . Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–1907
   PubMed Web of Science ®Google Scholar
• . Azzoli CG, Baker S Jr, Temin S,. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251–6266
   PubMed Web of Science ®Google Scholar
• . Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–4625
   PubMed Web of Science ®Google Scholar
• . Ionescu DN. Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada. Curr Oncol. 2013;20(4):220–226
   PubMed Web of Science ®Google Scholar
• . Murgu S, Colt H. Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. Clin Lung Cancer. 2013;14(6):609–626
   PubMed Web of Science ®Google Scholar
• . Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med. 2004;55:433–457
   PubMed Web of Science ®Google Scholar
• . Swinson DE, Cox G, O'Byrne KJ. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer. 2004;91(7):1301–1307
   PubMed Web of Science ®Google Scholar
• . Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Bioscience. 2001;6:D685–D707
   PubMed Web of Science ®Google Scholar
• . Pirker R, Pereira JR, Szczesna A,. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373(9674):1525–1531
   PubMed Web of Science ®Google Scholar
• . Mok TS, Wu YL, Thongprasert S,. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957
   PubMed Web of Science ®Google Scholar
• . D'Angelo SP, Pietanza MC, Johnson ML,. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol. 2011;29(15):2066–2070
   PubMed Web of Science ®Google Scholar
• . Sun PL, Seol H, Lee HJ,. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7(2):323–330
   PubMed Web of Science ®Google Scholar
• . Gridelli C, Rossi A. EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European population. J Thorac Dis. 2012;4(2):219–220
   PubMed Web of Science ®Google Scholar
• . Shepherd FA, Rodrigues Pereira J, Ciuleanu T,. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–132
   PubMed Web of Science ®Google Scholar
• . Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res. 2004;10(12 Pt 2):4233s–4237s
   Web of Science ®Google Scholar
• . Kim ES, Hirsh V, Mok T,. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809–1818
   PubMed Web of Science ®Google Scholar
• . Krawczyk P, Kowalski DM, Wojas-Krawczyk K,. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. Chemotherapy. 2012;58(1):60–69
   PubMed Web of Science ®Google Scholar
• . Garassino MC, Martelli O, Broggini M,. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981–988
   PubMed Web of Science ®Google Scholar
• . Sequist LV, Yang JC, Yamamoto N,. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334
   PubMed Web of Science ®Google Scholar
• . Ugocsai K, Mandoky L, Tiszlavicz L, Molnar J. Investigation of HER2 overexpression in non-small cell lung cancer. Anticancer Res. 2005;25(4):3061–3066
   PubMed Web of Science ®Google Scholar
• . Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol. 2004;31(1 Suppl 1):75–82
   PubMed Web of Science ®Google Scholar
• . Junker K, Stachetzki U, Rademacher D,. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer. 2005;48(1):59–67
   PubMed Web of Science ®Google Scholar
• . Gounaris IG. Trastuzumab in breast cancer. N Engl J Med. 2006;354(6):640–644; author reply, 640–644
   PubMedGoogle Scholar
• . Clamon G, Herndon J, Kern J,. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005;103(8):1670–1675
   PubMed Web of Science ®Google Scholar
• . Landi L, Cappuzzo F. HER2 and lung cancer. Expert Rev Anticancer Ther. 2013;13(10):1219–1228
   PubMed Web of Science ®Google Scholar
• . Kelly RJ, Carter CA, Giaccone G. HER2 mutations in non-small-cell lung cancer can be continually targeted. J Clin Oncol. 2012;30(26):3318–3319
   PubMed Web of Science ®Google Scholar
• . Wang SE, Narasanna A, Perez-Torres M,. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 2006;10(1):25–38
   PubMed Web of Science ®Google Scholar
• . Dai Z, Kelly JC, Meloni-Ehrig A,. Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. Mol Cytogenet. 2012;5(1):44
   PubMedGoogle Scholar
• . Shaw AT, Kim DW, Mehra R,. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197
   PubMed Web of Science ®Google Scholar
• . Yip PY, Yu B, Cooper WA,. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol. 2013;8(4):408–414
   PubMed Web of Science ®Google Scholar
• . Sun JM, Lira M, Pandya K,. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer. 2014;83(2):259–264
   PubMed Web of Science ®Google Scholar
• . Kwak EL, Bang YJ, Camidge DR,. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703
   PubMed Web of Science ®Google Scholar
• . Approval annoucement. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376058.htm
   Google Scholar
• . Kim YT, Kim TY, Lee DS,. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer. 2008;59(1):111–118
   PubMed Web of Science ®Google Scholar
• . Lewis TS, Hunt JB, Aveline LD,. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell. 2000;6(6):1343–1354
   PubMed Web of Science ®Google Scholar
• . Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis. 1999;20(8):1507–1510
   PubMed Web of Science ®Google Scholar
• . Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6(8):1353–1362
   PubMed Web of Science ®Google Scholar
• . Massarelli E, Varella-Garcia M, Tang X,. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007;13(10):2890–2896
   PubMed Web of Science ®Google Scholar
• . Linardou H, Dahabreh IJ, Kanaloupiti D,. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9(10):962–972
   PubMed Web of Science ®Google Scholar
• . Zhu CQ, da Cunha Santos G, Ding K,. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26(26):4268–4275
   PubMed Web of Science ®Google Scholar
• . Ding L, Getz G, Wheeler DA,. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069–1075
   PubMed Web of Science ®Google Scholar
• . Pratilas CA, Taylor BS, Ye Q,. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A. 2009;106(11):4519–4524
   PubMed Web of Science ®Google Scholar
• . Cappuzzo F, Ligorio C, Janne PA,. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL trial. J Clin Oncol. 2007;25(16):2248–2255
   PubMed Web of Science ®Google Scholar
• . Chang JWC, Liu HP, Hsieh MH,. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients. Lung Cancer. 2008;61(3):328–339
   PubMed Web of Science ®Google Scholar
• . Eberhard DA, Johnson BE, Amler LC,. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23(25):5900–5909
   PubMed Web of Science ®Google Scholar
• . Endoh H, Yatabe Y, Kosaka T, Kuwano H, Mitsudomi T. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol. 2006;1(7):629–634
   PubMed Web of Science ®Google Scholar
• . Giaccone G, Ruiz MG, Le Chevalier T,. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 2006;12(20):6049–6055
   PubMed Web of Science ®Google Scholar
• . Han SW, Kim TY, Jeon YK,. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res. 2006;12(8):2538–2544
   PubMed Web of Science ®Google Scholar
• . Hirsch FR, Varella-Garcia M, Bunn PA,. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(31):5034–5042
   PubMed Web of Science ®Google Scholar
• . Hirsch FR, Varella-Garcia M, Cappuzzo F,. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007;18(4):752–760
   PubMed Web of Science ®Google Scholar
• . Ichihara S, Toyooka S, Fujiwara Y,. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer. 2007;120(6):1239–1247
   PubMed Web of Science ®Google Scholar
• . Jackman DM, Yeap BY, Lindeman NI,. Phase II clinical trial of chemotherapy-naive patients ≥ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(7):760–766
   PubMed Web of Science ®Google Scholar
• . Loprevite M, Tiseo M, Chiaramondia M,. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2007;13(21):6518–6526
   PubMed Web of Science ®Google Scholar
• . Massarelli E, Varella-Garcia M, Tang XM,. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2007;13(10):2890–2896
   PubMed Web of Science ®Google Scholar
• . Miller VA, Riely GJ, Zakowski MF,. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26(9):1472–1478
   PubMed Web of Science ®Google Scholar
• . Pao W, Wang TY, Riely GJ,. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLos Med. 2005;2(1):57–61
   Web of Science ®Google Scholar
• . Sasaki H, Endo K, Okuda K,. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res Clin Oncol. 2008;134(5):569–577
   PubMed Web of Science ®Google Scholar
• . van Zandwijk N, Mathy A, Boerrigter L,. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 2007;18(1):99–103
   PubMed Web of Science ®Google Scholar
• . Zucali PA, Ruiz MG, Giovannetti E,. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol. 2008;19(9):1605–1612
   PubMed Web of Science ®Google Scholar
• . Herbst RS, Prager D, Hermann R,. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23(25):5892–5899
   PubMed Web of Science ®Google Scholar
• . O'Byrne KJ, Bondarenko I, Barrios C,. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. ASCO Meeting Abstracts. 2009;27(15S):8007
   Google Scholar
• . Janne PA, Shaw AT, Pereira JR,. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14(1):38–47
   PubMed Web of Science ®Google Scholar
• . Paik PK, Arcila ME, Fara M,. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046–2051
   PubMed Web of Science ®Google Scholar
• . Moreau S, Saiag P, Aegerter P,. Prognostic value of BRAF(V(6)(0) (0)) mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol. 2012;19(13):4314–4321
   PubMed Web of Science ®Google Scholar
• . Ueda M, Toji E, Nunobiki O,. Mutational analysis of the BRAF gene in human tumor cells. Human Cell. 2008;21(2):13–17
   PubMed Web of Science ®Google Scholar
• . Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002;62(23):7001–7003
   PubMed Web of Science ®Google Scholar
• . Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A. 1987;84(24):9270–9274
   PubMed Web of Science ®Google Scholar
• . Takeuchi K, Soda M, Togashi Y,. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378–381
   PubMed Web of Science ®Google Scholar
• . Bergethon K, Shaw AT, Ou SH,. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870
   PubMed Web of Science ®Google Scholar
• . Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012;7(7):1086–1090
   PubMed Web of Science ®Google Scholar
• . Bos M, Gardizi M, Schildhaus HU,. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer. 2013;81(1):142–143
   PubMed Web of Science ®Google Scholar
• . Wells SA Jr, Robinson BG, Gagel RF,. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–141
   PubMed Web of Science ®Google Scholar
• . Elisei R, Schlumberger MJ, Muller SP,. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646
   PubMed Web of Science ®Google Scholar
• . Suzuki M, Makinoshima H, Matsumoto S,. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci. 2013;104(7):896–903
   PubMed Web of Science ®Google Scholar
• . Drilon A, Wang L, Hasanovic A,. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630–635
   PubMed Web of Science ®Google Scholar
• . Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–925
   PubMed Web of Science ®Google Scholar
• . Bean J, Brennan C, Shih JY,. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104(52):20932–20937
   PubMed Web of Science ®Google Scholar
• . Carter CA, Giaccone G. Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2012;24(2):123–129
   PubMed Web of Science ®Google Scholar
• . Sgambato A, Casaluce F, Maione P,. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer. Curr Pharm Des. 2012;18(37):6155–6168
   PubMed Web of Science ®Google Scholar
• . Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009;4(1):5–11
   PubMed Web of Science ®Google Scholar